US Bioservices Expands Rare Disease Distribution

Founded in 1994, US Bioservices began as a regional pharmacy focused on infused therapies. Building on a foundation of patient-centered care, it now provides national in-home nursing services and clinical support for thousands of patients with chronic and complex illnesses.

US Bioservices was acquired by AmerisourceBergen in 2003. US Bioservices works in collaboration with other AmerisourceBergen business units to enhance patient care, support care in local communities and offer manufacturer partners integrated commercialization solutions. 

US Bioservices has recently been selected by Biocodex SAS to exclusively dispense Diacomit (stiripentol). The Food and Drug Administration approved Diacomit on Aug. 20, 2018 for the treatment of seizures associated with Dravet syndrome in patients two years of age and older taking Clobazam. Diacomit is approved by the FDA in two formulations – capsules and powder for oral suspension.

Dravet syndrome, also known as severe myoclonic epilepsy in infancy, is an orphan disease considered one of the most intractable forms of epilepsy, with first seizures occurring during the first year of life. DS is characterized by severe epilepsy, psychomotor retardation and a high mortality rate reported in up to 21% of these patients.

DS is thought to affect approximately 2,800 patients aged 2 to18 years in the United States, and Diacomit addresses key unmet medical needs in this poorly serviced population experiencing a catastrophic, life-threatening condition.

US Bioservices dispenses limited distribution and eclusive treatments for a number of rare diseases:

  • Congenital Sucrase-Isomaltase Deficiency (CSID)/Genetic Sucrase-Isomaltase Deficiency (GSID)
  • Dupuytren’s Contracture
  • Idiopathic Thrombocytopenic Purpura
  • DMD –  Duchenne’s Muscular Dystrophy
  • Peyronie’s Disease
  • Sickle Cell Anemia